IndraLab

Statements


| 1

reach
"We demonstrate that pharmacological inhibition of EAG2 reduces MB cell viability and motility, and identify an FDA approved antipsychotic drug, thioridazine, as a novel EAG2 channel blocker with potent efficacy in reducing intracranial xenograft MB growth and metastasis."